Phenylacetyl glutamine: a novel biomarker for stroke recurrence warning.

ABSTRACT:

Background

Stroke is the second leading cause of disease-related death and the third leading cause of disability worldwide. However, how to accurately warn of stroke onset remains extremely challenging. Recently, phenylacetyl glutamine (PAGln) has been implicated in the onset of stroke, but evidences from cohort studies of onset are lacking, especially in patients with first-onset or recurrent. It is necessary to deeply demonstrate the effectiveness of PAGln level on warning stroke onset.

Methods

One hundred fifteen first onset stroke patients, 33 recurrent stroke patients, and 135 non-stroke controls were included in the analysis. Risk factors associated with stroke attacking were evaluated, and plasma PAGln levels were detected via HPLC-MS based method. LASSO regression, P

SUBMITTER: Ma L 

PROVIDER: S-EPMC9933389 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature